Last reviewed · How we verify
NCT05397132
Mechanisms of Disease R/R in CAR-T for Hematologic Malignancies
trial testing Blood draw in Hematologic Malignancy in 50 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | Duke University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 27 May 2022 |
| Primary completion | 1 November 2026 |
| Estimated completion | 1 November 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Blood draw — full drug profile →
Conditions studied
- Hematologic Malignancy — all drugs for Hematologic Malignancy →
Sponsor
Duke University
Who can join
18 and older, any sex, with Hematologic Malignancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this IRB protocol is to perform immune profiling focusing on the measurement of Myeloid derived suppressor cells (MDSCs) over time in patients receiving Chimeric antigen receptor (CAR) T therapy and determine the correlation between immune profile and disease relapse/resistance in CAR T therapy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Single-cell RNA sequencing: enhancing the predictive accuracy of tumor immunotherapy efficacy.
Zhou W, Huang Z, Wu Z, Tang M, et al · · 2025 · cited 3× · PMID 40857744 · DOI 10.1042/ebc20253017 -
Immune profiling in oncology: bridging the gap between technology and treatment.
Ravi N, Tye GJ, Dhaliwal SS, Musa MY, et al · · 2025 · cited 3× · PMID 40856894 · DOI 10.1007/s12032-025-03002-x
Verify or expand the search:
- PubMed search for NCT05397132
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Blood draw
Trials testing the same drug.
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
- NCT07252622 — Progesterone Levels and Frozen Embryo Transfer Outcomes · not yet recruiting
- NCT07382076 — Clinical Evaluation of the i-STAT ACTpro Cartridge in an Adult Population · active not recruiting
- NCT06011824 — A Study of Effect of Megakaryocytes and Platelets in Breast Cancer · completed
- NCT05912400 — Evaluating Mitochondrial Dysfunction in Patients With Neurofibromatosis Type 1 · completed
Other recruiting trials for Hematologic Malignancy
Currently open trials in the same condition.
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07511127 — Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT · Phase 3 · recruiting
- NCT07413991 — Expressive Writing Program Among Young Adults With Blood Cancer · NA · active not recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT07035938 — T-cell Developmental Status in Patients With Malignant Hematological Tumors · recruiting
Other Duke University trials
Trials by the same sponsor.
- NCT07216456 — Vaginal Dilator Therapy After Pelvic Radiation · NA · not yet recruiting
- NCT07519317 — Dosing and Deployment Trial: A Home-based Optokinetic Treatment · NA · not yet recruiting
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07216963 — The Community Paramedic Response and Overdose Outreach With Supportive Medical-Legal Services Study · NA · not yet recruiting
- NCT07459218 — IDEAS for Hope to Reduce Suicide Risk and Improve HIV Care Engagement in Tanzania · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05397132 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Duke University
- Last refreshed: 2 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05397132.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing